CD4 and neoplasm: When the immunophenotypes of the tumor samples were compared with the blood samples, statistically significant differences in the incidences of the CD3+ CD69+, CD4+ CD69+, and CD8+ CD69+ T cells in the tumor samples were 7.83, 9.67, and 10.5 times higher, respectively.